

PHARMACOGENOMICS: APPLYING GENETIC TESTING TO OPTIMIZE MEDICATION THERAPY**SANGINIDI INDU HARINI**

Assistant Professor, Department of Pharmacy Practice, Koringa College of Pharmacy, Kirangi, Kakinada.

*Corresponding Author
Dr. Sanginidi Indu Harini

Article History: Received: 26 Mar 2026, Revised: 09 Apr 2026, Accepted: 09 May 2026

Abstract: Pharmacogenomics has emerged as a revolutionary field within precision medicine that investigates how genetic variations influence individual responses to medications. Variability in drug efficacy, toxicity, metabolism, and therapeutic outcomes among patients often results from inherited genetic differences affecting pharmacokinetic and pharmacodynamic pathways. Conventional medication prescribing strategies frequently rely on standardized dosing regimens that may not account for patient-specific genetic characteristics, thereby increasing the risk of adverse drug reactions, treatment failure, and healthcare costs. Pharmacogenomic testing offers opportunities to personalize medication therapy by identifying genetic polymorphisms associated with drug metabolism, transport, receptor sensitivity, and enzymatic activity. Advances in genomic sequencing technologies, molecular diagnostics, bioinformatics, and artificial intelligence have accelerated the clinical implementation of pharmacogenomics across multiple therapeutic areas including oncology, cardiology, psychiatry, infectious diseases, pain management, and neurology. Genetic biomarkers involving cytochrome P450 enzymes, human leukocyte antigens, thiopurine methyltransferase, and various transporter proteins now support evidence-based medication selection and dose optimization. Pharmacogenomic-guided therapy improves treatment efficacy, reduces adverse drug reactions, enhances medication adherence, and supports individualized healthcare delivery. Pharmacists play increasingly important roles in pharmacogenomic implementation through genetic test interpretation, medication therapy management, patient counseling, clinical decision support, adverse event prevention, and interdisciplinary collaboration. Despite substantial progress, significant challenges remain regarding clinical integration, healthcare provider education, ethical concerns, cost-effectiveness, reimbursement policies, data privacy, and equitable access to genetic testing services. This manuscript discusses the principles, technologies, clinical applications, pharmacist interventions, ethical considerations, implementation challenges, emerging innovations, and future perspectives of pharmacogenomics in optimizing medication therapy and advancing personalized healthcare systems.

Keywords: *Pharmacogenomics; Precision medicine; Genetic testing; Personalized therapy; Drug metabolism; Pharmacogenetics; Adverse drug reactions; Cytochrome P450; Pharmacist interventions; Genomic medicine.*

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License.
Copyright © 2026 Author(s) retains the copyright of this article.

**I. INTRODUCTION**

Pharmacogenomics is a rapidly evolving scientific discipline that examines how inherited genetic variations influence individual responses to medications [1]. Variability in drug efficacy, toxicity, metabolism, and therapeutic outcomes among patients has long been recognized in clinical medicine. Conventional prescribing strategies often apply standardized medication regimens despite significant interindividual differences in pharmacokinetics and pharmacodynamics [2]. Consequently, many patients experience adverse drug reactions, therapeutic failure, or suboptimal clinical outcomes due to genetic factors affecting drug metabolism and response. The integration of genomic science into healthcare has significantly expanded

understanding of genetic determinants influencing medication therapy. Pharmacogenomics combines principles of pharmacology, molecular genetics, genomics, and bioinformatics to identify genetic biomarkers associated with drug absorption, distribution, metabolism, excretion, and receptor interactions [3]. Variations within genes encoding drug-metabolizing enzymes, transport proteins, receptors, and immune response pathways contribute substantially to variability in therapeutic responses. Among the most extensively studied pharmacogenomic biomarkers are cytochrome P450 enzyme polymorphisms, particularly CYP2D6, CYP2C19, CYP2C9, and CYP3A4, which influence metabolism of numerous medications including antidepressants, antipsychotics, opioids, anticoagulants,

and cardiovascular agents [4]. Additional clinically relevant genes include thiopurine methyltransferase, human leukocyte antigens, UDP-glucuronosyltransferases, and solute carrier transport proteins. Identification of these genetic variations enables healthcare providers to personalize medication selection and dosage strategies. Recent advancements in next-generation sequencing, molecular diagnostics, artificial intelligence, and computational genomics have accelerated clinical implementation of pharmacogenomic testing [5]. Pharmacogenomics now supports precision medicine approaches across oncology, psychiatry, cardiology, infectious diseases, neurology, pain management, and transplantation medicine. Clinical guidelines developed by organizations such as the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group provide evidence-based recommendations for genotype-guided prescribing [6]. Pharmacists play critical roles in pharmacogenomic implementation through medication therapy management, genetic test interpretation, patient counseling, clinical decision support, and interdisciplinary collaboration [7]. However, substantial barriers remain regarding healthcare infrastructure, clinician education, ethical concerns, reimbursement policies, regulatory frameworks, and equitable access to genetic testing services. This manuscript reviews the principles, technologies, clinical applications, pharmacist interventions, implementation challenges, ethical considerations, and future opportunities of pharmacogenomics in optimizing medication therapy and advancing personalized healthcare delivery.

2. HISTORICAL EVOLUTION OF PHARMACOGENOMICS

The concept of genetically determined variability in drug response originated several decades ago following observations that certain individuals experienced unusual reactions to commonly prescribed medications [8]. Early studies identified inherited differences in acetylation pathways influencing responses to isoniazid therapy for tuberculosis. Subsequent research demonstrated that genetic polymorphisms significantly affected metabolism of numerous drugs. The term “pharmacogenetics” initially described investigation of single-gene influences on medication response, whereas “pharmacogenomics” later emerged to encompass genome-wide analysis of multiple genetic determinants [9]. Advances in molecular biology, polymerase chain reaction technologies, and DNA sequencing significantly accelerated discovery of clinically relevant pharmacogenomic biomarkers. Completion of the Human Genome Project in 2003 represented a major milestone in genomic medicine [10]. Rapid advances in sequencing technologies, bioinformatics, and computational biology subsequently expanded opportunities for precision medicine and individualized therapeutics. Today, pharmacogenomics has evolved into an integral component of modern

precision healthcare systems with increasing implementation across hospitals, research institutions, and pharmaceutical industries.

3. PRINCIPLES OF PHARMACOGENOMICS

Pharmacogenomics investigates how genetic variations influence pharmacokinetic and pharmacodynamic processes. Pharmacokinetics involves drug absorption, distribution, metabolism, and excretion, whereas pharmacodynamics examines interactions between drugs and their biological targets [11]. Genetic polymorphisms affecting drug-metabolizing enzymes represent among the most clinically significant determinants of medication response. Cytochrome P450 enzymes located primarily within the liver metabolize approximately 75% of clinically utilized medications [12]. Variations in genes encoding these enzymes may result in poor, intermediate, normal, rapid, or ultrarapid drug metabolism phenotypes. Poor metabolizers may accumulate toxic drug concentrations, increasing risks of adverse drug reactions. Conversely, ultrarapid metabolizers may eliminate medications rapidly, reducing therapeutic efficacy [13]. Pharmacogenomic testing therefore enables clinicians to individualize medication selection and dosing strategies according to predicted metabolic capacity. Pharmacodynamic variations involving receptors, ion channels, enzymes, and signaling pathways also influence therapeutic responses. Genetic differences in receptor sensitivity may alter medication effectiveness and toxicity profiles. Immune-mediated pharmacogenomic responses are particularly important in hypersensitivity reactions. Human leukocyte antigen variants have been associated with severe adverse reactions to medications including carbamazepine, abacavir, and allopurinol [14].

4. GENETIC TESTING TECHNOLOGIES IN PHARMACOGENOMICS

Technological advances have significantly improved accessibility and accuracy of pharmacogenomic testing. Polymerase chain reaction remains among the most widely utilized molecular diagnostic techniques for identifying specific genetic polymorphisms [15]. Microarray-based technologies enable simultaneous analysis of multiple genetic variants associated with medication response. These platforms facilitate high-throughput pharmacogenomic screening for clinical and research applications. Next-generation sequencing technologies have revolutionized genomic medicine by enabling comprehensive genome-wide analysis with improved speed and reduced cost [16]. Whole-genome sequencing, whole-exome sequencing, and targeted gene panels increasingly support personalized medicine initiatives. Bioinformatics and artificial intelligence further enhance interpretation of complex genomic datasets. Machine learning algorithms identify genotype-phenotype associations, predict therapeutic outcomes, and support clinical decision-making [17]. Point-of-care pharmacogenomic testing

systems are also under development to facilitate rapid bedside therapeutic optimization in acute clinical settings.

5. CYTOCHROME P450 ENZYMES AND DRUG METABOLISM

Cytochrome P450 enzymes represent among the most extensively studied pharmacogenomic biomarkers. CYP2D6 metabolizes approximately 25% of clinically prescribed medications including antidepressants, opioids, beta-blockers, and antipsychotics [18]. Genetic polymorphisms within CYP2D6 produce substantial variability in enzyme activity. Poor metabolizers may experience toxicity from standard medication doses, whereas ultrarapid metabolizers may exhibit therapeutic failure due to accelerated drug clearance. CYP2C19 polymorphisms significantly influence metabolism of proton pump inhibitors, antidepressants, and antiplatelet medications such as clopidogrel [19]. Patients with reduced CYP2C19 activity demonstrate impaired conversion of clopidogrel into its active metabolite, increasing cardiovascular risks. CYP2C9 variants affect metabolism of warfarin, phenytoin, and nonsteroidal anti-inflammatory drugs. Combined testing for CYP2C9 and VKORC1 genes improves warfarin dosing accuracy and reduces bleeding complications [20]. Additional clinically important enzymes include CYP3A4, CYP1A2, CYP2B6, and UDP-glucuronosyltransferases.

6. PHARMACOGENOMICS IN ONCOLOGY

Oncology represents among the most advanced applications of pharmacogenomics due to the increasing importance of targeted therapies and precision medicine [21]. Tumor genomic profiling identifies mutations and biomarkers guiding selection of anticancer therapies. HER2 overexpression predicts responsiveness to trastuzumab therapy in breast cancer patients. Epidermal growth factor receptor mutations influence therapeutic selection in non-small cell lung cancer [22].

Thiopurine methyltransferase testing is widely utilized before administration of thiopurine medications including mercaptopurine and azathioprine. Patients with reduced TPMT activity experience increased risks of severe myelosuppression [23]. DPYD gene testing identifies patients at risk for fluoropyrimidine toxicity. Reduced dihydropyrimidine dehydrogenase activity increases risks of life-threatening adverse reactions during fluorouracil therapy. Pharmacogenomics additionally supports immunotherapy optimization, targeted drug selection, and personalized cancer treatment planning.

Cardiovascular Pharmacogenomics

Cardiovascular medications demonstrate substantial interindividual variability in therapeutic response and adverse effect profiles. Pharmacogenomic testing improves selection and dosing of anticoagulants, antiplatelet agents, antihypertensives, and lipid-lowering therapies [24]. Warfarin therapy represents a well-

established example of pharmacogenomic-guided dosing. Genetic variants within CYP2C9 and VKORC1 significantly influence warfarin metabolism and sensitivity [25]. Genotype-guided dosing algorithms improve anticoagulation stability and reduce bleeding risks.

CYP2C19 testing is increasingly utilized before clopidogrel therapy. Reduced-function alleles impair conversion of clopidogrel into its active metabolite, increasing risks of thrombotic events [26]. SLCO1B1 polymorphisms influence statin metabolism and susceptibility to statin-induced myopathy. Pharmacogenomic testing may improve lipid-lowering therapy safety.

Pharmacogenomics in Psychiatry and Neurology:

Psychiatric medications frequently demonstrate unpredictable therapeutic responses and adverse effects. Pharmacogenomic testing assists selection of antidepressants, antipsychotics, mood stabilizers, and anxiolytics [27].

CYP2D6 and CYP2C19 polymorphisms significantly affect metabolism of selective serotonin reuptake inhibitors, tricyclic antidepressants, and antipsychotic medications. Genotype-guided prescribing improves treatment efficacy and reduces adverse effects. HLA-B*1502 testing is recommended before carbamazepine therapy among specific Asian populations due to increased risks of Stevens-Johnson syndrome and toxic epidermal necrolysis [28]. Pharmacogenomics may additionally improve epilepsy management, pain therapy, and neurodegenerative disease treatment.

Pharmacogenomics in Infectious Diseases:

Genetic testing also supports individualized therapy within infectious disease management. HLA-B*5701 testing is routinely performed before abacavir administration to prevent severe hypersensitivity reactions among HIV patients [29].

Interleukin-28B polymorphisms influence treatment responses among hepatitis C patients receiving interferon-based therapies. Pharmacogenomics may also support antimicrobial stewardship initiatives and optimization of antiviral therapies.

Pharmacist Interventions in Pharmacogenomics

Pharmacists play central roles in clinical implementation of pharmacogenomics due to their expertise in pharmacotherapy, medication safety, and individualized patient care [30]. Clinical pharmacists interpret pharmacogenomic test results, recommend genotype-guided therapeutic adjustments, and monitor treatment outcomes.

Medication therapy management programs increasingly incorporate pharmacogenomic information to optimize medication regimens and reduce adverse drug reactions. Pharmacists collaborate with physicians, genetic counselors, nurses, and laboratory specialists within interdisciplinary precision medicine teams. Patient counseling represents another essential pharmacist responsibility. Pharmacists educate patients regarding pharmacogenomic testing procedures, therapeutic implications, medication risks, and

personalized treatment strategies [31]. Hospital pharmacists contribute to development of institutional pharmacogenomic protocols, electronic clinical decision support systems, and formulary guidelines. Community pharmacists may facilitate access to direct-to-consumer pharmacogenomic services and medication counseling. Pharmacists additionally participate in pharmacovigilance programs aimed at monitoring genotype-associated adverse drug reactions and therapeutic outcomes.

7. ETHICAL, LEGAL, AND SOCIAL CONSIDERATIONS

Pharmacogenomics raises important ethical and legal concerns regarding patient privacy, informed consent, data security, discrimination, and equitable access to healthcare services [32]. Genetic information represents highly sensitive personal data requiring strong confidentiality protections.

Concerns regarding genetic discrimination by employers and insurance providers remain significant barriers to patient acceptance of pharmacogenomic testing. Regulatory frameworks such as the Genetic Information Nondiscrimination Act provide legal protections within certain healthcare systems. Informed consent processes must adequately address risks, benefits, limitations, and potential implications of genetic testing. Healthcare providers should ensure that patients understand possible incidental findings and privacy concerns. Healthcare disparities also represent major challenges in pharmacogenomic implementation. Limited access to genomic technologies among underserved populations may worsen existing healthcare inequities [33].

8. CHALLENGES IN CLINICAL IMPLEMENTATION

Despite substantial scientific progress, widespread implementation of pharmacogenomics remains limited by several barriers. Healthcare provider education and genomic literacy remain insufficient among many clinicians [34]. Lack of familiarity with pharmacogenomic interpretation may reduce clinical confidence and adoption.

Cost and reimbursement limitations also restrict accessibility of pharmacogenomic testing services. Insurance coverage policies vary substantially across healthcare systems. Integration of genomic data into electronic health records and clinical workflows presents additional technical challenges. Clinical decision support systems must effectively translate complex genomic information into actionable prescribing recommendations. Regulatory and standardization issues remain under development. Variability in testing methodologies, reporting systems, and interpretation guidelines may complicate clinical implementation. Further research is additionally required to strengthen evidence regarding long-term clinical utility and cost-effectiveness of pharmacogenomic-guided therapy.

6. ARTIFICIAL INTELLIGENCE AND FUTURE INNOVATIONS

Artificial intelligence and machine learning technologies are expected to significantly expand future applications of pharmacogenomics [35]. AI-driven algorithms analyze complex genomic and clinical datasets to predict medication responses and optimize therapeutic selection.

Integration of multi-omics approaches including genomics, proteomics, metabolomics, and transcriptomics may further enhance precision medicine capabilities [36]. Personalized drug development and individualized therapeutic planning are expected to become increasingly feasible. Point-of-care genomic testing platforms may facilitate rapid bedside pharmacogenomic-guided prescribing in emergency medicine and critical care settings. Wearable technologies and digital health systems may additionally support continuous therapeutic monitoring. Gene-editing technologies including CRISPR-Cas9 may eventually enable correction of genetic abnormalities associated with adverse drug responses and inherited diseases.

7. FUTURE PERSPECTIVES

Pharmacogenomics is expected to become an increasingly integral component of routine clinical practice and precision healthcare systems. Expansion of genomic databases, decreasing sequencing costs, and advancements in computational medicine will likely accelerate clinical implementation [37].

Educational initiatives targeting healthcare professionals are essential for improving pharmacogenomic literacy and interdisciplinary collaboration. Pharmacists are expected to assume expanding leadership roles in genomic medicine and personalized therapeutics. Global standardization of pharmacogenomic guidelines, regulatory frameworks, and ethical policies will remain necessary for ensuring safe and equitable implementation. Public health strategies should additionally address healthcare disparities and improve access to genomic services among underserved populations.

8. CONCLUSION

Pharmacogenomics represents a transformative advancement in precision medicine by enabling individualized medication therapy based on patient-specific genetic characteristics. Genetic variations influencing drug metabolism, pharmacodynamics, immune responses, and therapeutic efficacy significantly contribute to interindividual variability in clinical outcomes. Pharmacogenomic testing supports optimized medication selection, dose individualization, adverse drug reaction prevention, and improved therapeutic effectiveness across multiple medical specialties. Recent advancements in genomic sequencing, molecular diagnostics, bioinformatics, and artificial intelligence have accelerated clinical implementation of pharmacogenomics within oncology,

cardiology, psychiatry, infectious diseases, and neurology. Pharmacists continue to play essential roles through genetic test interpretation, medication therapy management, patient counseling, pharmacovigilance, and interdisciplinary collaboration. Despite substantial progress, important challenges remain regarding healthcare provider education, ethical considerations, reimbursement policies, regulatory frameworks, data privacy, and equitable access to genetic testing services. Continued technological innovation, evidence-based research, professional education, and healthcare policy development will remain essential for successful integration of pharmacogenomics into routine clinical practice and future personalized healthcare systems.

9. FUNDING

Nil

10. INFORM CONSENT AND ETHICAL STATEMENT

Not applicable

11. ACKNOWLEDGEMENT

Not Declared

12. REFERENCES

- Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. *N Engl J Med.* 2003;348(6):538-549.
- Meyer UA. Pharmacogenetics and adverse drug reactions. *Lancet.* 2000;356(9242):1667-1671.
- Relling MV, Evans WE. Pharmacogenomics in the clinic. *Nature.* 2015;526(7573):343-350.
- Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther.* 2013;138(1):103-141.
- Shendure J, Ji H. Next-generation DNA sequencing. *Nat Biotechnol.* 2008;26(10):1135-1145.
- Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. *Clin Pharmacol Ther.* 2014;95(4):423-428.
- Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. *Clin Pharmacol Ther.* 2012;92(4):467-475.
- Kalow W. *Pharmacogenetics: hereditary basis of drug response.* Philadelphia: Saunders; 1962.
- Vogel F. *Moderne Probleme der Humangenetik.* *Ergeb Inn Med Kinderheilkd.* 1959;12:52-125.
- Collins FS, Morgan M, Patrinos A. The Human Genome Project: lessons from large-scale biology. *Science.* 2003;300(5617):286-290.
- Brunton LL, Hilal-Dandan R, Knollmann BC, editors. *Goodman and Gilman's the pharmacological basis of therapeutics.* 13th ed. New York: McGraw-Hill Education; 2018.
- Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. *Trends Pharmacol Sci.* 2004;25(4):193-200.
- Stingl JC, Brockmüller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. *Clin Pharmacol Ther.* 2013;93(5):442-449.
- Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *N Engl J Med.* 2002;347(7):472-480.
- Mullis K, Faloona F. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. *Methods Enzymol.* 1987;155:335-350.
- Metzker ML. Sequencing technologies-the next generation. *Nat Rev Genet.* 2010;11(1):31-46.
- Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med.* 2019;25(1):44-56.
- Gaedigk A, Sangkuhl K, Whirl-Carrillo M, et al. The evolution of PharmVar. *Clin Pharmacol Ther.* 2017;102(4):667-680.
- Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy. *Clin Pharmacol Ther.* 2013;94(3):317-323.
- Johnson JA, Cavallari LH. Warfarin pharmacogenetics. *Trends Cardiovasc Med.* 2015;25(1):33-41.
- Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. *N Engl J Med.* 2013;369(11):1021-1031.
- Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2004;350(21):2129-2139.
- Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther.* 2011;89(3):387-391.
- Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 polymorphisms and response to clopidogrel. *N Engl J Med.* 2009;360(4):354-362.
- Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. *Clin Pharmacol Ther.* 2009;85(4):455-459.
- Pereira NL, Rihal CS, So DYF, et al. Clopidogrel pharmacogenetics. *J Am Coll Cardiol.* 2019;73(13):161-170.
- Hicks JK, Bishop JR, Gammal RS, et al. A call for clear and consistent communications regarding the role of pharmacogenetics in antidepressant

- pharmacotherapy. *Clin Pharmacol Ther.* 2020;107(4):770-777.
28. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. *Nature.* 2004;428(6982):486.
 29. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. *N Engl J Med.* 2008;358(6):568-579.
 30. Berenbrok LA, Gabriel N, Coley KC, Hernandez I. Evaluation of pharmacists' preparedness for pharmacogenomics implementation. *J Am Pharm Assoc (2003).* 2020;60(6):e86-e93.
 31. Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. *Clin Pharmacol Ther.* 2015;97(2):153-155.
 32. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. *Pharmacogenomics J.* 2012;12(2):93-97.
 33. Petrovski S, Goldstein DB. Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine. *Nat Med.* 2016;22(2):209-210.
 34. Stanek EJ, Sanders CL, Taber KAJ, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. *Am J Med.* 2012;125(8):786-792.
 35. Beam AL, Kohane IS. Big data and machine learning in health care. *JAMA.* 2018;319(13):1317-1318.
 36. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. *Genome Biol.* 2017;18(1):83.
 37. Ashley EA. Towards precision medicine. *Nat Rev Genet.* 2016;17(9):507-522.